Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2933 - Levels of miR-17, miR-21, miR-29a and miR-92 as recurrence markers after adjuvant chemotherapy in Nx lymph node status colon cancer patients


10 Oct 2016


Poster display


Nikolay Conev


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


N.V. Conev1, A. Konsoulova-Kirova2, J. Kashlov3, I. Tonev4, I. Donev2

Author affiliations

  • 1 Dept. Of Medical Oncology, St. Marina University Hospital, 9000 - Varna/BG
  • 2 Dept. Of Medical Oncology, St. Marina University Hospital, 9010 - Varna/BG
  • 3 Dept. Of Internal Diseases, St. Marina University Hospital, 9010 - Varna/BG
  • 4 Oncology Clinic, Complex Cancer Center, 4004 - Plovdiv/BG


Abstract 2933


The benefit of adjuvant chemotherapy in II and III stage patients with colon cancer (CC) is determined in large-scale trials. Despite the surprisingly large number of Nx cases (less than 12 lymph nodes examined), the potential benefit of adjuvant chemotherapy is not known and there are only a few biomarkers that could predict recurrence of the disease. Recent evidence suggests that microRNAs are important cancer markers.


CC patients (n = 18) with Nx lymph node status, who have undergone radical surgery and have completed 5-FU based adjuvant chemotherapy were included. Serum after last cycle of adjuvant chemotherapy was obtained and patients were followed-up regularly for 1 year of follow-up. Real-time reverse transcription quantitative polymerase chain reaction was used to measure the expression levels of miRNAs (miR-17, miR-21, miR-29a and miR-92), in the patients' samples and in 7 healthy individuals, as a control group.


Seven patients from the tested group experienced recurrence after 1 year of follow-up. Within the Nx patients all miRNAs except miR-29a had significant differences in expression levels between the recurred patients vs non recurred patients groups. The area under the receiver operating characteristic curve (AUCs) used to evaluate the predictive performance of the miR-17, miR-21, miR-92 for Nx patients were 0.844, 0.948, and 0.935, respectively (p 


This study suggests that the expression levels of the tested serum miR-21, miR-17 and miR-92 in Nx patients with CC who underwent radical surgery and adjuvant chemotherapy may have diagnostic value for differentiating between recurred and non-recurred patients.

Clinical trial identification

Legal entity responsible for the study

Ivan Donev


Medical University Varna


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings